WAY Stock Forecast & Price Target

Waystar Holding is favored because its mission-critical RCM platform is deeply embedded in healthcare workflows, supported by 30,000+ clients, 5k+ payor connections, 500+ EHR integrations, and roughly 8.5B annual transactions. Its durable growth case is reinforced by >97% gross revenue retention, 108–110% NRR, ~70% EBITDA-to-FCF conversion, and a framework for low double-digit revenue growth with 40%+ adjusted EBITDA margins, while management also cites a $44.1B TAM and ~5% penetration. The bullish view is further supported by proprietary claims data that powers Altitude AI, including ~18–20 new products, a $18B LTM denials savings claim, and the possibility that major private equity backers, who own a combined 30%, may seek a sale or go-private transaction.

Waystar Holding is viewed negatively because its growth may slow after a $34mm topline benefit from the 2024 Change Healthcare disruption, making the 19.3% 2024 revenue growth difficult to sustain as management suggested the broader end market is closer to 5%. The company also faces elongated enterprise sales cycles, with hospitals taking 12–18 months to close versus about 4 weeks in ambulatory, which can delay bookings and revenue recognition. About 50% of revenue is volume-based, so utilization swings, policy changes, cybersecurity incidents, and competition could pressure forecasting, margins, and multiple expansion.